MoonLake reports positive Phase 3 IZAR-1 results in psoriatic arthritis, Q2 2026 earnings
The trial hit all Week 16 endpoints for the 60 mg sonelokimab arm, and MoonLake says it has cash into mid-2028.
SEC filing
Latest
2 stories
Sign inSign in2 stories
The trial hit all Week 16 endpoints for the 60 mg sonelokimab arm, and MoonLake says it has cash into mid-2028.
SEC filing